This webinar presents the paucity of scientific facts and in-research potential medical uses of cannabidiol (CBD) with the abundant unproven health claims from the caveat emptor retail marketing boom of unregulated CBD consumer products. It compares properties, pharmacological effects and the legal status of CBD and THC (delta 9-tetrahydrocannabinol), and the hemp and marijuana varieties of Cannabis sativa; it reviews the historic 2018 U.S. FDA approval of Epidiolex®, an oral solution of cannabidiol for rare treatment-resistant childhood epilepsies as the first Cannabis-derived drug; and it reviews the endogenous cannabinoid or eCB pharmacology receptors and their agonists.